王紫斓,涂应锋,于波

• 1:哈尔滨医科大学附属第二医院心内科

摘要(Abstract)：

目前经皮冠状动脉介入治疗是临床上急性冠状动脉综合征常用的治疗策略。从最初的裸金属支架到现在的药物洗脱支架,支架内再狭窄和支架内血栓形成的风险大幅度降低,使支架后再发急性冠状动脉综合征的发病率有所下降,但仍然是临床医师需面临的严峻并发症之一。因此,全面了解其发生发展机制,同时临床上早期发现与治疗是提高再发急性冠状动脉综合征存活率、改善预后的主要方式。本文主要分析总结了目前支架置入术后再发急性冠状动脉综合征的发病机制、影像学诊断及治疗策略的研究成果及进展。

关键词(KeyWords)： 经皮冠状动脉介入治疗;急性冠状动脉综合征;支架内再狭窄;支架内血栓形成

Abstract:

Keywords:

基金项目(Foundation): 国家重点研发计划资助（2016YFC131101）

作者(Author): 王紫斓,涂应锋,于波

参考文献(References)：

• [1] Mazin I, Paul G, Asher E. Neoatherosclerosis-from basic concept to clinical implication. Thromb Res, 2019, 178:12-16.
• [2] Leone A, Rebuzzi A, Burzotta F, et al. Stent malapposition, strut coverage and atherothrombotic prolapse after percutaneous coronary interventions in ST-segment elevation myocardial infarction. J Cardiovasc Med(Hagerstown), 2019, 20(3):122-130.
• [3] Adriaenssens T, Joner MD, Godschalk TC, et al. Optical coherence tomography fi ndings in patients with coronary stent thrombosis:A report of the prestige consortium(prevention of late stent thrombosis by an interdisciplinary global european eff ort). Circulation, 2017,136(11):1007-1021.
• [4] Andreou I, Stone PH, Ikonomidis I, et al. Recurrent atherosclerosis complications as a mechanism for stent failure. Hellenic J Cardiol,2019, 61(1):9-14.
• [5] Foin N, Gutiérrez-Chico JL, Nakatani S, et al. Incomplete stent apposition causes high shear fl ow disturbances and delay in neointimal coverage as a function of strut to wall detachment distance implications for the management of incomplete stent apposition. Circ Cardiovasc Interv, 2014, 7(2):180-189.
• [6] Shlofmitz E, Iantorno M, Waksman R. Restenosis of drug-eluting stents:A new classifi cation system based on disease mechanism to guide treatment and state-of-the-art review. Circ Cardiovasc Interv,2019, 12(8):e007023.
• [7] Xi Y, Chen J, Bi Y, et al. Long-term clinical safety and e ffi cacy of drug-coated balloon in the treatment of in-stent restenosis:A metaanalysis and systematic review. Catheter Cardiovasc Interv, 2019,96(2):E129-E141.
• [8] Waksman R, Iantorno M. Refractory in-stent restenosis:Improving outcomes by standardizing our approach. Curr Cardiol Rep, 2018,20(12):140.
• [9] Park K, Kang S, Kim D, et al. Late endothelial progenitor cellcapture stents with CD146 antibody and nanostructure reduce in-stent restenosis and thrombosis. Acta Biomater, 2020, 111:91-101.
• [10] Song J, Shen J, Fan J, et al. Eff ects of a matrix metalloproteinase inhibitor-eluting stent on in-stent restenosis. Med Sci Monit, 2020,26:e922556.
• [11] Kajiya T, Yamaguchi H, Takaoka J, et al. In-stent restenosis assessed with frequency-domain optical coherence tomography shows smooth coronary arterial healing process in second-generation drug-eluting stents. Singapore Med J, 2019, 60(1):48-51.
• [12] Feng C, Zhang P, Han B, et al. Optical coherence tomographic analysis of drug-eluting in-stent restenosis at dif ferent times:A STROBE compliant study. Medicine(Baltimore), 2018, 97(34):e12117.
• [13] Huang C, Yang G, Jiang T, et al. Ef fects of IL-6 and AG490 on regulation of Stat3 signaling pathway and invasion of human pancreatic cancer cells in vitro. J Exp Clin Cancer Res, 2010, 29(1):51.
• [14] Wang J, Song C, Xiao Y, et al. In vivo and in vitro analyses of the eff ects of a novel high-nitrogen low-nickel coronary stent on reducing in-stent restenosis. J Biomater Appl, 2018, 33(1):64-71.
• [15]温小琴，黄奎，高明东，等.介入治疗致冠脉内皮损伤程度对循环内皮祖细胞动员的影响.四川生理科学杂志，2017, 39(4):194-197.
• [16] Dangas G, Claessen B, Caixeta A, et al. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol, 2010, 56(23):1897-1907.
• [17] Yin D, Mintz G, Song L, et al. In-stent restenosis characteristics and repeat stenting underexpansion:insights from optical coherence tomography. EuroIntervention, 2020, 16(4):e335-e343.
• [18] Morofuji T, Inaba S, Aisu H, et al. Heterogeneous intravascular ultrasound fi ndings of stent thrombosis. Intern Med, 2017, 56(3):259-268.
• [19] Sakamoto Y, Yamawaki M, Araki M, et al. Comparison of12-month angiographic outcomes between repeat drug-eluting stent implantation and drug-coated balloon treatment for restenotic lesion caused by stent fracture. Heart Vessels, 2019, 34(10):1589-1594.
• [20] Lenz T, Nicol P, Castellanos M, et al. Are we curing one evil with another? A translational approach targeting the role of neoatherosclerosis in late stent failure. Eur Heart J Suppl,2020,22(Suppl C):C15-C25.
• [21] Miyazaki S, Hiasa Y, Takahashi T, et al. In vivo optical coherence tomography of very late drug-eluting stent thrombosis compared with late in-stent restenosis. Circ J, 2012, 76(2):390-398.
• [22] Jia H, Hu S, Liu H, et al. Chronic total occlusion is associated with a higher incidence of malapposition and uncovered stent struts:OCT findings at 6 months following DES implantation. Catheter Cardiovasc Interv, 2017, 89(S1):582-591.
• [23] Rao J, Pan Bei H, Yang Y, et al. Nitric oxide-producing cardiovascular stent coatings for prevention of thrombosis and restenosis. Front Bioeng Biotechnol, 2020, 8:578.
• [24] Martín-Reyes R, Jiménez-Valero S, Navarro F, et al. Subacute drug-eluting stent thrombosis caused by stent underexpansion:evaluation by optical coherence tomography. Case Rep Med, 2011,2011:129341.
• [25] Cuesta J, Rivero F, Bastante T, et al. Optical coherence tomography findings in patients with stent thrombosis. Rev Esp Cardiol(Engl Ed), 2017, 70(12):1050-1058.
• [26] Souteyrand G, Amabile N, Mangin L, et al. Mechanisms of stent thrombosis analysed by optical coherence tomography:insights from the national PESTO French registry. Eur Heart J, 2016, 37(15):1208-1216.
• [27] Park S, Kang S, Virmani R, et al. In-stent neoatherosclerosis:a final common pathway of late stent failure. J Am Coll Cardiol,2012, 59(23):2051-2057.
• [28] Hong S, Lee S, Hong M. Clinical implication of optical coherence tomography-based neoatherosclerosis. J Korean Med Sci, 2017, 32(7):1056-1061.
• [29] Nomoto Y, Nakagawa M, Shirai N, et al. Neointimal coverage after second generation drug-eluting stent implantation has a relationship with pre-existing atherosclerotic lesion characteristics.Medicine(Baltimore), 2019, 98(37):e17097.
• [30] Amabile N, Souteyrand G, Ghostine S, et al. Very late stent thrombosis related to incomplete neointimal coverage or neoatherosclerotic plaque rupture identifi ed by optical coherence tomography imaging. Eur Heart J Cardiovasc Imaging, 2013, 15(1):24-31.
• [31] Karjalainen P. Neointimal coverage and vasodilator response to titanium-nitride-oxide-coated bioactive stents and everolimus-eluting stents in patients with acute coronary syndrome:insights from the BASE-ACS trial. Int J Cardiovasc Imaging, 2013, 29(8):1693-1703.
• [32] Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis:strut coverage as a marker of endothelialization. Circulation, 2007, 115(18):2435-2441.
• [33] Nakazawa G,Finn AV,Joner M,et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients:an autopsy study. Circulation,2008,118:1138–1145.
• [34] Kakizaki R, Minami Y, Hashikata T, et al. Impact of underlying plaque type on strut coverage in the early phase after drug-eluting stent implantation. Coron Artery Dis, 2018, 29(8):624-631.
• [35] Lee S, Im E, Hong S, et al. Severe acute stent malapposition after drugeluting stent implantation:Ef fects on long-term clinical outcomes. J Am Heart Assoc, 2019, 8(13):e012800.
• [36] Lee S, Ahn J, Mintz G, et al. Ten-year clinical outcomes of lateacquired stent malapposition after coronary stent implantation.Arterioscler Thromb Vasc Biol, 2020, 40(1):288-295.
• [37] Caixeta A, Braga V, Mintz G. Very late stent thrombosis with bare-metal stent:identif ying severe stent malapposition and underexpansion by intravascular ultrasound. Einstein(Sao Paulo),2013, 11(3):364-366.
• [38] Lee CH, Hur S. Optimization of percutaneous coronary intervention using optical coherence tomography. Korean Circ J, 2019, 49(9):771-793.
• [39] Ro ffi M, Patrono C, Collet J, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task f orce f or the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology(ESC). G Ital Cardiol(Rome), 2016, 17(10):831-872.
• [40] Alfonso F, Virmani R. Intracoronary imaging for the diagnosis of the underlying substrate and clinical management of acute coronary syndromes:from evidence to expert consensus and back!Euro Intervention, 2019, 15(5):392-395.
• [41] Park JK, Kim J, Kwon HM, et al. Multidetector computed tomography for the evaluation of coronary artery disease; the diagnostic accuracy in calcifi ed coronary arteries, comparing with IVUS imaging. Yonsei Med J, 2014, 55(3):599-605.
• [42] Negi SI, Torguson R, Gai J, et al. Intracoronary brachytherapy for recurrent drug-eluting stent failure. JACC Cardiovasc Interv, 2016,9(12):1259-1265.
• [43] Fuentes L, Gmez-Lara J, Salvatella N, et al. IVUS fi ndings in late and very late stent thrombosis. A comparison between bare-metal and drug-eluting stents. Rev Esp Cardiol(Engl Ed), 2018, 71(5):335-343.
• [44] Hirota Y, Nomura T, Ono K, et al. Vulnerable neoatherosclerosis in coronary artery with whole circumference showing intravascular echo attenuation. Clin Case Rep, 2019, 7(5):1094-1097.
• [45] Choi KH, Song YB, Lee JM, et al. Impact of intravascular ultrasound-guided percutaneous coronary intervention on long-term clinical outcomes in patients undergoing complex procedures. JACC Cardiovasc Interv, 2019, 12(7):607-620.
• [46] Tan Y, Sheng Z, Zhou P, et al. Plasma trimethylamine n-oxide as a novel biomarker for plaque rupture in patients with ST-segmentelevation myocardial infarction. Circ Cardiovasc Interv, 2019, 12(1):e007281.
• [47] Hafiane A. Vulnerable plaque, characteristics, detection, and potential therapies. J Cardiovasc Dev Dis, 2019, 6(3):26.
• [48] Baan J, Claessen BE, Dijk KB, et al. A randomized comparison of paclitaxel-eluting balloon versus everolimus-eluting stent for the treatment of any in-stent restenosis:The DARE trial. JACC Cardiovasc Interv, 2017, 11(3):275-283.
• [49] Barbato L, Grasso MA, Spagnolo S. In-stent restenosis in the left anterior descending coronary artery:what is the solution for diff use disease? Patch reconstruction and coronary artery bypass grafting--surgery as the fi rst option in complex coronary artery disease. Eur J Cardiothorac Surg, 2019, 55(6):1238.
• [50] Jun S, Keisuke S, Takashi Y, et al. Rotational atherectomy followed by drug-coated balloon dilation for left main in-stent restenosis in the setting of acute coronary syndrome complicated with right coronary chronic total occlusion. Int Heart J, 2017, 58(5):806-811.
• [51] Alfonso F, Pérez-Vizcayno MJ, García del Blanco B, et al.Usefulness of drug-eluting balloons for bare-metal and drug-eluting in-stent restenosis(from the RIBSⅣandⅤrandomized trials). Am J Cardiol, 2017, 119(7):983-990.
• [52] DeSilvey DL. Treatment of coronary in-stent restenosis with a paclitaxelcoated balloon catheter. Am J Geriatr Cardiol, 2007, 16(2):115-116.
• [53] Kook H, Joo HJ, Park JH, et al. A comparison between drug-eluting stent implantation and drug-coated balloon angioplasty in patients with left main bifurcation in-stent restenotic lesions. BMC Cardiovasc Disord, 2020, 20(1):83.
• [54] Rittger H, Brachmann J, Sinha A, et al. A randomized, multicenter,single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis:the PEPCADDES study. J Am Coll Cardiol, 2012, 59(15):1377-1382.
• [55] Badr S, Ben-Dor I, Dvir D, et al. The state of the excimer laser for coronary intervention in the drug-eluting stent era. Cardiovasc Revasc Med, 2013, 14(2):93-98.
• [56] Nishino M, Mori N, Takiuchi S, et al. Indications and outcomes of excimer laser coronary atherectomy:Efficacy and safety for thrombotic lesions--The ULTRAMAN registry. J Cardiol, 2017, 69(1):314-319.
• [57]赵昕，荆全民，王兆丰，等.准分子激光冠状动脉斑块消蚀术在急性冠状动脉综合征介入治疗中应用的效果.中华心血管病杂志，2018, 46(10):795.
• [58] Pereira G, Dallan L, Vergara-Martel A, et al. Treatment of instent restenosis using excimer laser coronary atherectomy and bioresorbable vascular scaffold guided by optimal coherence tomography. Cardiovasc Revasc Med, 2021, 22:44-49.
• [59] Witkowski A, Kalinczuk?，Chmielak Z, et al. Acute lumen overdilation improves outcome after brachytherapy of in-stent restenosis. Cardiovasc Revasc Med, 2006, 7(4):202-207.
• [60] Varghese M, Bhatheja S, Baber U, et al. Intravascular brachytherapy for the management of repeated multimetal-layered drug-eluting coronary stent restenosis. Circ Cardiovasc Interv, 2018, 11(10):e006832.
• [61] Schiele TM, Konig A, Rieber J, et al. Sirolimus-eluting stent implantation andβ-irradiation for the treatment of in-stent restenotic lesions:Comparison of underlying mechanisms of acute gain and late loss as assessed by volumetric intravascular ultrasound. Am Heart J, 2005, 150(2):351-357.
• [62] Levine G, Bates E, Blankenship J, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines and the society for cardiovascular angiography and interventions. J Am Coll Cardiol, 2011, 58(24):e44-e122.
• [63] Armstrong EJ, Feldman DN, Wang TY, et al. Clinical presentation,management, and outcomes of angiographically documented early,late, and very late stent thrombosis. JACC Cardiovasc Interv, 2012,5(2):131-140.
• [64] Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med, 2006, 355(20):2113-2124.
• [65] Yang H, Jin S, Jang H, et al. Sildenafi l reduces neointimal hyperplasia after angioplasty and inhibits platelet aggregation via activation of c GMP-dependent protein kinase. Sci Rep, 2019, 9(1):7769.